1 / 8

Articulating the Unmet Need in the Diagnosis and Treatment of Pseudobulbar Affect:

Articulating the Unmet Need in the Diagnosis and Treatment of Pseudobulbar Affect: Prevalence of the Condition and Limitations of Existing Therapies. Ursula Hess, PhD Torre Lazur McCann West. Estimated US Patients With PBA: 1.7 Million. No QOL studies

mercedes-garner
Télécharger la présentation

Articulating the Unmet Need in the Diagnosis and Treatment of Pseudobulbar Affect:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Articulating the Unmet Need in the Diagnosis and Treatment of Pseudobulbar Affect: Prevalence of the Condition and Limitations of Existing Therapies Ursula Hess, PhD Torre Lazur McCann West

  2. Estimated US Patients With PBA: 1.7 Million

  3. No QOL studies PBA can be severe, persistent, and deteriorate Widely recognized that PBA can be profoundly disabling socially and occupationally Embarrassing and distressing Can impair ability to communicate May be dangerous during eating or drinking Related to decreased sexual activity poststroke Fear of attacks, secondary phobias and social withdrawal often make symptoms worse Interferes with rehabilitation PBA Impact on Quality of Life (QOL)

  4. Evidenced by plethora of names for condition Lack of agreement on defining features Episodes are sudden, involuntary, difficult to control, excessive, disproportionate, and labile Mood congruent or incongruent? Limited to laughing and crying? Etiology unknown Caused by structural brain damage, but seen after bilateral, diffuse as well as single, focal lesions Possible that lesions within different neural systems result in different manifestations of the syndrome Poorly Clinically Defined Condition With Unknown Disease Mechanism

  5. Validated scales exist to measure PBA but are infrequently and inconsistently used PLACS,interviewer-rated instrument (Robinson et al, 1993) CNS-LS, self-report measure (Moore et al, 1997) PBA is distinct from, but can coexist with, affective disorders such as depression Crying spells in depression and laughing episodes in schizophrenia, hysteria, and mania may mimic PBA symptoms Neurological disease as a cause of crying is vastly underestimated by referring physicians (Green et al, 1987) PBA Is Underrecognized and Sometimes Misdiagnosed

  6. Antidepressants (TCAs, SSRIs) and dopaminergic agents used with varying success Complete resolution of symptoms or no response DA agents only ~40%-50% successful Available agents do NOT have proven efficacy in large, well-controlled clinical trials using standardized scales 5 comparative antidepressant trials with N≤28 2/5 trials did not use objective scales TCAs have an unfavorable side effect profile, and their use may be limited in PBA patients Even severe cases often remain untreated No Approved Pharmacotherapy With Indication for PBA

  7. Specific indication for PBA Proven effective and safe in large (N=140), well-controlled trial using the CNS-LS Significantly improved QOL and QOR; not shown for existing therapies Offers a potentially more targeted approach to the treatment of PBA than existing agents NeurodexTM

  8. Raise awareness of PBA Facilitate seeking of counseling and treatment NeurodexTM Implement the use of standardized scales for diagnosis and assessment of therapy CNS-LS Physician and Patient Education Needed

More Related